SNWV

Business Context and Reporting Period

Company: SANUWAVE Health, Inc. (SNWV)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2025
Business Overview: SANUWAVE focuses on commercializing patented regenerative medicine utilizing noninvasive ultrasound and shockwaves (UltraMIST® and PACE®) for tissue repair. The company operates as a smaller reporting company with a single reportable segment.

Key Financial Metrics

Note: Working Capital calculated as Current Assets ($20,168) minus Current Liabilities ($46,501).

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 42% year-over-year (YoY) for the quarter and 51% YoY for the six-month period. This was driven by a 61% increase in system sales and a 29% increase in disposable sales, alongside price discipline.
• Profitability Shift: While the company reported a net income of $1.1M for the quarter, the six-month period resulted in a net loss of $4.6M. This contrasts with a net income of $2.0M for the six months ended June 30, 2024.
• Expense Increases: General and Administrative (G&A) expenses surged 120% YoY for the quarter, primarily due to increased headcount ($1.1M) and stock-based compensation ($0.9M).
• Non-Operating Volatility: The six-month net loss was significantly impacted by a $3.9M loss from the change in fair value of derivative liabilities (warrants), compared to a gain in the prior year. Additionally, the prior year included a $5.2M gain on debt extinguishment that did not recur.
• Balance Sheet: Inventory increased to $5.9M from $4.1M at year-end 2024 to support growth. Senior secured debt carrying value increased to $26.8M.

Outlook, Risks, and Management Commentary

• Going Concern Warning: The filing explicitly states that substantial doubt exists regarding the company's ability to continue as a going concern for 12 months. This is due to an accumulated deficit of $256M, negative working capital, and the Senior Secured Note maturing in September 2025.
• Refinancing Efforts: Management is actively engaged in discussions with lenders to refinance the debt maturing in September 2025 to extend maturity and provide liquidity. No assurances are given regarding the success or terms of these efforts.
• Internal Controls: The company identified material weaknesses in internal controls over financial reporting as of June 30, 2025, which remain unremediated. Weaknesses include lack of controls over key accounting processes, IT, and complex financial instruments. A remediation plan involving new software and personnel is underway.
• Stock-Based Compensation: Significant performance-based awards were granted in 2025. As of June 30, 2025, management concluded that revenue and EBITDA performance conditions were not probable of achievement, though market-based awards continue to be expensed.
• Tax Attributes: An IRC Section 382 analysis indicated that $44.2M of Net Operating Loss (NOL) tax attributes would expire before becoming available due to ownership shifts.

Investor Verification Checklist

• Debt Maturity: Verify the status of refinancing discussions for the $26.8M Senior Secured Note due in September 2025.
• Liquidity Runway: Assess if current cash ($8.5M) is sufficient to cover operations and debt service until refinancing is secured.
• Internal Controls: Monitor progress on remediation of material weaknesses in financial reporting and IT controls.
• Derivative Liability: Track the fair value of warrant liabilities, which fluctuated significantly ($3.9M loss in six months) and impact net income.
• Revenue Sustainability: Confirm if the 42% revenue growth rate is sustainable given the heavy reliance on UltraMIST consumables and systems.